REVIEW

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

Brandon M. Bordeau, Joseph P. Balthasar
Department of Pharmaceutical Science, University at Buffalo, Buffalo, NY 14214, USA

ABSTRACT

Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vasculature and a dense extracellular matrix that slow both the convective and diffusive transport of mAbs into and within tumors. For mAbs that are directed against cellular antigens, high antigen expression and rapid antigen turnover can result in perivascular cells binding to and eliminating a significant amount of extravasated mAb, limiting mAb distribution to portions of the tumor that are distant from functional vessels. Many preclinical investigations have reported strategies to improve mAb uptake and distribution; however, to our knowledge, none have translated into the clinic. Here, we provide an overview of several barriers in solid tumors that limit mAb uptake and distribution and discuss approaches that have been utilized to overcome these barriers in preclinical studies.

KEYWORDS

Solid tumors; antibody uptake and distribution; monoclonal antibody; antibody–drug conjugate

Introduction

In 1900, Paul Ehrlich developed the receptor theory, which was built on the foundational hypothesis that toxins, nutrients, and drugs exert their observed effect through binding to unique proteins that are present within cells. As a natural consequence of receptor theory, Ehrlich believed that drugs could be developed that can specifically bind to and neutralize a disease-causing organism while sparring the host cells. Ehrlich famously developed the term “magic bullet” to describe the mechanism by which cells developed immunity to toxins and was inspired to apply this concept to the development of small-molecule drugs with the postulate “we have to learn how to aim chemically.” Ehrlich is considered to be the founder of modern chemotherapy; his research led to the development of Salvarsan as a treatment for syphilis, and his many theories were foundational to the development of the first anti-cancer drugs.

Currently, monoclonal antibodies (mAbs) are heralded as the “magic bullets” that Ehrlich envisioned, and in many cases, the moniker is well deserved. Antibodies can bind most substances with high affinity and high selectivity and are used for the treatment of many diseases. A case in which mAbs do not live up to their hyperbolic nickname is as therapies directed against solid tumors. Although 18 mAbs are approved for solid-tumor indications, it is generally accepted that the observed efficacy is disappointing. Table 1 provides a list of all Food and Drug Administration (FDA)–approved mAbs for solid tumor indications and the clinical trial outcomes that resulted in approval. On average, for mAbs that were investigated in 2-arm clinical trials, an increase in progression-free survival of 3 months and a 10.3% increase in the objective response rate were observed in the mAb treatment arm. Despite the marginal benefit, the cost of mAb therapy for oncology is high, with a median cost of $142,833 per year. Currently, the clinical methods that are being used to improve mAb efficacy focus on improving patient selection through genomic or proteomic screening prior to mAb therapy. For example, trastuzumab requires human epidermal growth factor receptor 2 (HER2) screening with an immunohistochemical or fluorescence in situ hybridization assay to ensure HER2 overexpression prior to therapy. However, in many cases, the assessment of target expression alone is not sufficient to predict a patient’s response to mAb therapy.
| Antibody (mAb) | Format              | Indication          | Target | Year approved | Trial arm | Comparator | Notes                                                                 |
|----------------|---------------------|---------------------|--------|---------------|-----------|------------|------------------------------------------------------------------------|
| Trastuzumab    | Humanized IgG1 mAb  | Breast cancer       | HER2   | 1998          | mAb + chemotherapy vs. chemotherapy | MTP: 7.2 months ORR: 45% DOR: 83 months 1-year survival: 79% | MTP: 4.5 months ORR: 29% DOR: 5.8 months 1-year survival: 68% | Approved in combination with paclitaxel for patients without prior chemotherapy or as a single agent in patients who have progressed on chemotherapy |
| Cetuximab      | Chimeric IgG1 mAb   | Colorectal cancer   | EGFR   | 2004          | mAb + irinotecan vs. mAb            | ORR: 22.9% MTP: 4.1 months | ORR: 10.8% MTP: 1.5 months | Assessed in patients who progressed on irinotecan. Approved in combination with irinotecan for patient's refractory to irinotecan or as a single agent for patients intolerant to irinotecan |
| Bevacizumab    | Humanized IgG1      | Colorectal cancer   | VEGF   | 2004          | mAb + IFL vs. IFL + placebo         | MTP: 20.3 months PFS: 10.6 months ORR: 45% DOR: 10.4 months | MTP: 15.6 months PFS: 6.4 months ORR: 35% DOR: 7.1 months | Tested in combination with 5-fluorouracil, irinotecan, leucovorin |
| Panitumumab    | Humanized IgG2 mAb  | Colorectal cancer   | EGFR   | 2006          | mAb + best supportive care vs. best supportive care | PFS: 96 days ORR: 8% | PFS: 60 days ORR: 0% | Assessed in patients who progressed on fluoropyrimidine, oxaliplatin, and irinotecan. No difference in overall survival observed |
| Pertuzumab     | Humanized IgG1      | Breast cancer       | HER2   | 2012          | mAb + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel | PFS: 18.5 months ORR: 80.2% DOR: 20.2 months Survival: 82.8% | PFS: 12.4 months ORR: 69.3% DOR: 12.5 months Survival: 76.4% | Approved in combination with trastuzumab and docetaxel for patients who have not received prior therapy |
| Ado-trastuzumab emtansine | Humanized IgG1 ADC | Breast cancer       | HER2   | 2012          | ADC vs. lapatinib + capecitabine   | PFS: 9.6 months ORR: 43.6% DOR: 12.6 months MS: 30.9 months | PFS: 6.4 months ORR: 30.8% DOR: 6.5 months MS: 25.1 months | Tested in patients with metastatic or locally advanced breast cancer with prior trastuzumab or prior taxane therapy |
| Ramucirumab    | Human IgG1          | Gastric cancer      | VEGFR2 | 2014          | mAb + best supportive care vs. best supportive care + placebo | PFS: 2.1 months MS: 5.2 months | PFS: 1.3 months MS: 3.8 months | Tested in patients with locally advanced or metastatic gastric cancer who previously received platinum or fluoropyrimidine chemo |
| Nivolumab      | Human IgG4          | Melanoma/NSCLC      | PD1    | 2014          | Single-arm trial                   | ORR: 32% | N/A | Tested in patients with unresectable or metastatic melanoma that progressed on ipilimumab |
| Pembrolizumab  | Humanized IgG4      | Melanoma            | PD1    | 2014          | Single-arm trial                   | ORR: 24% | N/A | Tested in patients with unresectable or metastatic melanoma that progressed on ipilimumab |
| Antibody (mAb)          | Format          | Indication      | Target       | Year approved | Trial arm             | Comparator | Notes                                                                                     |
|-------------------------|-----------------|-----------------|--------------|---------------|-----------------------|------------|-------------------------------------------------------------------------------------------|
| Necitumumab (Portrazza) | Human IgG1      | NSCLC           | EGFR         | 2015          | mAb + gemcitabine + cisplatin vs. gemcitabine + cisplatin | PFS: 5.7 months OS: 23% ORR: 31% MS: 11.5 months | PFS: 5.5 months OS: 19% ORR: 29% MS: 9.9 months | Tested as a first line chemotherapy in patients with metastatic squamous NSCLC |
| Dinutuximab (Unituxin)  | Chimeric IgG1   | Neuroblastoma   | GD2          | 2015          | mAb + RA vs. RA       | OS: 73% EFS: 71% | OS: 58% EFS: 56% | Tested in pediatric patients with high risk neuroblastoma. "RA = 13-cis-retinoic acid"  |
| Olaratumab (Lartruvo)   | Human IgG1      | Soft tissue sarcoma | PDGFR- alpha | 2016          | mAb + doxorubicin vs. doxorubicin | OS: 41% MS: 26.5 months PFS: 8.2 months ORR: 18.2% | OS: 22% MS: 14.7 months PFS: 4.4 months ORR: 7.5% | Eligible patients were required to have soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy, a histologic type of sarcoma for which an anthracycline-containing regimen was appropriate but had not been administered |
| Atezolizumab (Tecentriq)| Humanized IgG1  | Bladder cancer  | PD-L1        | 2016          | Single-arm trial      | ORR: 14.8% | N/A | Tested in patients with locally advanced or metastatic urothelial carcinoma that progressed on platinum containing chemotherapy. |
| Avelumab (Bavencio)     | Human IgG1      | Merkel cell carcinoma | PD-L1      | 2017          | Single-arm trial      | ORR: 33% | N/A | Tested in patients who progressed on chemotherpay for distant metastatic disease  |
| Durvalumab (IMFINZI)    | Human IgG1      | Bladder cancer  | PD-L1        | 2017          | Single-arm trial      | ORR: 17% | N/A | Tested in patients with metastatic urothelial cancer that progressed on or after a platinum-based therapy |
| Cemiplimab (Libtayo)    | Human mAb       | Cutaneous squamous cell carcinoma | PD-1       | 2018          | Single-arm trial      | ORR: 47.2% | N/A | Tested in patients with metastatic or locally advanced CSCC that were not candidates for curative surgery or radiation |
| Enfortumab vedotin (Padcev) | Human IgG1 ADC | Urothelial cancer | Nectin-4    | 2019          | Single-arm trial      | ORR: 44% DOR: 7.6 months | N/A | Tested in patients with locally advanced or metastatic urothelial cancer with prior PD-1 or platinum-based chemo |
| [fam-] trastuzumab deruxtecan-nxki (Enhertu) | Humanized IgG1 ADC | Metastatic breast cancer | HER2 | 2019          | Single-arm trial      | ORR: 60.3% DOR: 14.8 M | N/A | Tested in patients with HER2-positive, unresectable and/or metastatic breast cancer who had received 2 or more prior anti-HER2 therapies |
| Sacituzumab govitecan-hziy (Teddy) | Humanized IgG1 ADC | Triple-neg. breast cancer | TROP-2    | 2020          | Single-arm trial      | ORR: 33.3% DOR: 7.7 M | N/A | Tested in patients with metastatic triple negative breast cancer who progressed on 2 prior treatments. |

mAb, antibody; ADC, antibody drug conjugate; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; MS, median survival; DOR, median duration of response; EFS, event-free survival.
Antibodies exert therapeutic effects through a variety of mechanisms. Antibodies may antagonize tumor growth pathways by binding to cell membrane-associated receptors, inhibiting their activation or enhancing their degradation or by binding to and neutralizing soluble growth factors. Antibodies that bind cell membrane receptors can also recruit immune effector cells through fragment crystallizable (Fc) gamma receptor binding, leading to tumor cell killing through antibody-dependent cellular cytotoxicity by natural killer (NK) cells or antibody-dependent cell phagocytosis by monocytes and macrophages. Antibodies that bind to cell membrane receptors can also trigger complement-dependent cytotoxicity with tumor cell lysis resulting from the formation of the membrane attack complex and the recruitment of NK cells, macrophages, neutrophils, dendritic cells, and T-cells following complement receptor stimulation. Many of the anti-cancer mAbs recently approved by the FDA bind to the programmed death receptor or ligand 1 (PD-1), blocking a key mechanism of immune escape for many tumors. Antibodies are also used for the delivery of cytotoxic drugs, radionuclides, and immunotoxins. A common barrier that limits the efficacy of all mAb-based therapies is poor uptake and distribution within solid tumors, which results in suboptimal exposure to portions of the tumor, development of resistance, and tumor progression. The abnormal physiology of solid tumors and its relevance to antibody delivery have been reviewed elsewhere. Here, we provide a brief overview of the individual tumor barriers and focus on a discussion of strategies that have been explored to overcome each barrier for the enhancement of mAb tumor uptake and penetration (Figure 1).

**Vasculature**

The blood vasculature within solid tumors is composed of many immature and disorganized vessels, resulting in poor blood flow and hypoxia. The structural deficiencies of solid tumor blood vessels and the overexpression of proangiogenic factors that increase vasculature permeability result in plasma leakage into the interstitial space. High interstitial fluid pressure limits the efficacy of mAb-based therapies. The vasculature within solid tumors is composed of many immature and disorganized vessels, resulting in poor blood flow and hypoxia. The structural deficiencies of solid tumor blood vessels and the overexpression of proangiogenic factors that increase vasculature permeability result in plasma leakage into the interstitial space. High interstitial fluid pressure limits the efficacy of mAb-based therapies.

**Figure 1** Shown is a graphic representation of barriers that limit therapeutic antibody uptake and distribution into solid tumors and the approaches that have been reported to mitigate the tumor barriers. A graphic key is provided in the bottom left inset. Figure 1 was created using BioRender.com.
oncotic pressure can collapse tumor blood vessels and can limit the convective transport of mAbs from the blood into tumor interstitial fluid\textsuperscript{[17,18,23]}. In solid tumors, the rate of mAb extravasation is much slower than the rates of interstitial diffusion and antigen binding\textsuperscript{26}. As a result, many strategies have been explored to modulate tumor vasculature to improve mAb uptake (Table 2). The most notable approach to modify the vasculature in tumors is to modulate angiogenesis and vessel porosity with agents such as the anti-vascular endothelial growth factor (VEGF) mAb bevacizumab. Bevacizumab can “normalize” tumor vasculature by pruning immature and leaky vessels, improving blood flow, and decreasing interstitial fluid pressure (IFP)\textsuperscript{[24,25]}. Enhanced blood flow and decreased IFP improves mAb tumor uptake; however, the window between normalization and excessive pruning is dependent on both the dose of the anti-angiogenic and the time after administration and has proven difficult to capture\textsuperscript{24,25,27}. Our group observed a 63% decrease in the tumor area under the curve (AUC) up to 10 days after administration of the anti-carcinoembryonic antigen (CEA) mAb T84.66 in LS174T xenograft-bearing mice that were treated with 5 mg/kg bevacizumab twice a week\textsuperscript{28}. Decreased tumor uptake with bevacizumab co-administration has also been observed with the anti-HER2 mAb trastuzumab in multiple xenograft models\textsuperscript{29-31}. In a phase II trial, the combination of bevacizumab with trastuzumab and docetaxel did not improve patient survival\textsuperscript{32}. Administration of 5 mg/kg bevacizumab to mice bearing OSC19 and SCC1 xenografts, 3 days prior to the administration of 10 mg/kg IRDye800 cetuximab, resulted in an increase in cetuximab tumor fluorescence\textsuperscript{33}. A single 10-mg/kg dose of bevacizumab to mice bearing SUM149 xenografts, 4 days prior to the administration of 2.2 μg of indium-111 (\textsuperscript{111}In)--radiolabeled mAb, decreased the tumor uptake of cetuximab by 40% and decreased the uptake of an anti-insulin growth factor 1 receptor mAb R1507 by 35%-34%. Bevacizumab has been evaluated in 2 phase III clinical trials with both cetuximab and panitumumab. The combination of bevacizumab with cetuximab did not significantly improve patient survival\textsuperscript{35}, and the combination of panitumumab and bevacizumab decreased progression-free survival\textsuperscript{36}. The disappointing clinical trial results for mAb–bevacizumab co-therapy are in contrast to the results obtained for chemotherapy–bevacizumab combinations\textsuperscript{37-39}. The disconnect may result from the difference in the rate-limiting step for tumor uptake of small-molecule drugs (SMDs) in comparison to mAbs. SMDs have high vascular permeability and can rapidly diffuse into tumors from the blood. For tumor regions with poor blood flow, SMDs can enter the tumor space more quickly than the blood flow delivering the therapeutic agents (e.g., flow-limited distribution)\textsuperscript{40}. Antibodies have much slower permeability rates than small molecules. As a result, tumor uptake of mAb is dependent on the permeability surface area product\textsuperscript{40}. Improved tumor blood flow from vasculature normalization may enhance SMD uptake, while the decrease in tumor vasculature surface area, which results from the removal of immature tumor vessels, may contribute to the decrease in mAb tumor uptake observed with bevacizumab therapy.

To increase mAb tumor uptake, many preclinical investigations have explored the use of agents that enhance vascular permeability and blood flow. Early work by several groups reported co-administration of mAb with the vasculature promoting agents: angiotensin II, tumor necrosis factor-alpha, interferon, and interleukin 2 led to between 40% and 200% increases in mAb tumor uptake\textsuperscript{41-44}. The utility of these agents was limited by the short plasma half-life of the signaling ligands and the lack of tumor specificity of the vascular permeability enhancement leading to increased mAb deposition in healthy organs\textsuperscript{41,43,44}. To overcome these limitations, the Epstein group made chemical conjugates of 7 vascular promoting agents with the anti-necrosis mAb TNT-1 F(ab’)2\textsuperscript{45}. A TNT-1 F(ab’)2 conjugate with interleukin 2 led to the greatest enhancement in the tumor uptake of \textsuperscript{125}I-TNT-1 (Fab’), with a 275% increase in tumor radioactivity 3 days after administration\textsuperscript{45}. The domain of interleukin 2 responsible for increasing vasculature permeability was isolated to a 37 amino acid sequence termed permeability-enhancing peptide (PEP)\textsuperscript{46}. Administration of mAb-PEP conjugates, 2 h prior to administration of \textsuperscript{125}I-mAb, increased the uptake of TNT-1 and Lym-1 mAbs by 4-fold, 3 days after administration\textsuperscript{46}. The neuropilin-1 receptor, which, upon ligand binding, accumulates at the inter-endothelial cell contacts and induces vascular permeability, is the target for 2 peptides that have been reported to increase mAb tumor uptake\textsuperscript{47}. Sugahara et al.\textsuperscript{48} developed a cyclic 9mer peptide, named iRGD, that binds αv-integrins that are expressed on tumor endothelium. An internal cleavage sequence results in proteolytic digestion of the iRGD peptide and αv-integrin dissociation\textsuperscript{48}. The cleaved iRGD peptide has a CendR motif that binds to neuropilin-1 and, as a result, increases vascular permeability\textsuperscript{48}. Co-administration of 4 μmol/kg iRGD with 3 mg/kg trastuzumab to mice bearing orthotopic BT474 xenografts increased trastuzumab uptake by 40-fold, 3 h after administration\textsuperscript{49}. Shin et al.\textsuperscript{49} reported a peptide that
Table 2  Vasculature modulation approaches

| Treatment                                      | Impact on tumor                                                                 | Impact on mAb tumor PK | mAb/tumor model            | Source |
|-----------------------------------------------|--------------------------------------------------------------------------------|------------------------|---------------------------|--------|
| Bevacizumab                                   | Decrease in tumor vasculature and permeability                                  | 63% decrease in AUC (0–10 days) | T84.66 LS174T             | 28     |
| Sorafenib                                     | Decrease in tumor vasculature and permeability                                  | 41% decrease in AUC (0–7 days) | T84.66 LS174T             | 131    |
| Angiotensin II                                | Increase in trans vascular pressure gradient, enhanced tumor blood flow         | 40% increase in uptake 4 h after administration | CC49 LS174T | 41     |
| TNF-alpha administered intravenously (IV) or intratumorally (IT) | Enhanced vasopermeability (IT) 200% increase at 3 h, 27% increase at 22 h (IV) 100% increase at 3 h | Mab35 LOVO              |              |        |
| Interferon                                    | Enhanced blood flow                                                            | 83% increase in uptake 1.5 h after administration | MEM136 WM-9 | 43     |
| Interleukin 2 conjugate                        | Enhanced vasopermeability                                                      | 275% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| TNF-alpha conjugate                           | Enhanced vasopermeability and blood flow                                       | 213% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| Interleukin 1 conjugate                        | Enhanced vasopermeability and blood flow                                       | 200% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| Leukotriene-B4 conjugate                      | Enhanced blood flow                                                            | 122% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| Histamine conjugate                           | Enhanced vasopermeability                                                      | 118% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| Physalaemin conjugate                         | Enhanced blood flow                                                            | 71% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| Bradykinin conjugate                          | Enhanced blood flow                                                            | 23% increase in uptake 3 days after administration | TNT-1 F(ab’)2 ME-180     | 45     |
| PEP2-Ab conjugate                             | Enhanced vasopermeability                                                      | 249% increase in uptake 3 days after administration | B72.3 LS174T             | 46     |
| A22p-Ab conjugate                             | Enhanced vasopermeability                                                      | 50%–100% increase in uptake at 3 and 12 h after administration | Cetuximab/A459 Trastuzumab/SKOV3 | 49     |
| iRGD                                          | Enhanced vasopermeability                                                      | 3,900% Increase at 3 h by ELISA | Trastuzumab BT-474        | 48     |
| Mannitol Infusion                             | Osmotic opening of BBB                                                          | 234% and 32% increase in F(ab’)2 and mAb AUC (0.5–72 h) | P1.17 LX-1 SCLC | 58     |
| Focused ultrasound                            | Transient disruption of BBB                                                     | 5,577% increase in uptake 2 h after administration | Bevacizumab U87 glioma    | 63     |
| Angiopep-2-Ab conjugate                       | RMT through BBB by LRP1 binding                                                 | ~300% increase in tumor uptake 24 h after administration | Trastuzumab BT-474        | 68     |
| Human melanotransferrin-Ab conjugate          | RMT through BBB by LRP1 binding                                                 | 415% increase in tumor uptake 2 h after administration | Trastuzumab MDA-MB-231-BHER2/gfp | 69     |
was derived from the neuropilin-1 ligand semaphorin 3A, that was modified for enhanced neuropilin-1 binding affinity, named A22p. Genetic fusion of the A22p peptide to the carboxy terminus of the Fc domain of cetuximab or trastuzumab increased mAb tumor uptake between 1.5- and 2-fold at 3 and 12 h post-administration. Both the iRGD peptide and A22p peptide were reported to significantly improve the preclinical efficacy of trastuzumab. To our knowledge, there are no clinical trials involving any of the listed blood flow/permeability enhancers in combination with approved anti-cancer mAbs. The iRGD peptide is currently being evaluated in combination with nab-paclitaxel and gemcitabine for metastatic pancreatic cancer in a phase II trial (registration No. NCT03517176).

The effective targeting of brain tumors with mAb-based therapies is hampered by the blood–brain barrier (BBB). The BBB is highly selective and limits the extravasation of mAbs through the brain vasculature and into the brain interstitial fluid. Using a combination of microdialysis and tissue ELISA, Chang et al. reported that the concentration of trastuzumab in plasma, Wang et al. reported similar cerebrospinal fluid concentrations of 5 ng/g of tissue) to 3,257 ng/g. Combining FUS with trastuzumab increased the brain/blood concentration ratio of trastuzumab and significantly improved the therapeutic effect of bevacizumab in mice bearing U87 brain xenografts in comparison to bevacizumab alone (mean survival time of 73 vs. 46 days). Brighi et al. reported that FUS significantly increased the uptake of the anti-EphA2 mAb 4B3 in a patient derived xenograft mouse model of high-grade glioma; however, significant increases were only observed in the non-contrast-enhancing tumors (indicative of tumors with a functional BBB). There are 4 clinical trials evaluating FUS in combination with traditional chemotherapies (registration Nos. NCT03712293, NCT02343991, NCT03322813, and NCT03616860); however, to our knowledge there are no clinical trials evaluating FUS with mAb therapies. Significant efforts have been placed into development of antibody conjugates that can bind to receptors that are expressed on the BBB to allow brain uptake through receptor-mediated transcytosis (RMT). The transferrin receptor (TfR) and insulin receptor (IR) are common targets for antibody RMT. Conjugation of melanotransferrin, a substrate of low-density lipoprotein-like receptor 1 (LRP1). Conjugation of the peptide angiopep-2, which binds to LRP1, resulted in a 6-fold increase in brain/serum ratios for an anti-HER2 antibody and increased the median survival of mice bearing BT474 xenografts by 20%, relative to unconjugated antibody. Conjugation of melanotransferrin, a substrate of LRP1, to trastuzumab resulted in a 10- to 225-fold increase in the brain/blood concentration ratio of trastuzumab and reduced the size and number of metastatic brain tumors in mice administered MDA-MB-231-BRHER2/eGFP breast cancer cells.
Extracellular matrix

The hyperpermeability of solid tumor vasculature results in the deposition of the plasma proteins fibrin and fibrinogen into the interstitial space of solid tumors. Fibrinogen forms a scaffold that binds inflammatory factors and recruits macrophages and fibroblasts. Over time, the recruited inflammatory cells form a mature matrix, which is, in part, composed of collagen and hyaluronan. Hyaluronan is a negatively charged glycosaminoglycan that causes electromechanical repulsion and water absorption, leading to tumor swelling. Highly crosslinked collagen fibers resist the tumor swelling induced by hyaluronan and cell proliferation, which causes tensile stress that collapses tumor vasculature and lymphatics, contributing to the high tumor IFP. Post-extravasation, the dense extracellular matrix slows mAb diffusion, limiting tumor penetration. The limiting effect of the tumor extracellular matrix on mAb uptake and penetration is well appreciated; as a result, significant effort has been dedicated to developing methods that overcome tumor matrix barriers and enhance mAb tumor uptake and penetration.

Table 3 Extracellular matrix modulation approaches

| Treatment                                      | Impact on tumor                        | Impact on mAb tumor PK                        | mAb/tumor model     | Source |
|------------------------------------------------|----------------------------------------|-----------------------------------------------|---------------------|--------|
| Intratumoral collagenase                       | Collagen degradation                   | 80%–100% increase in diffusion 24 h after collagenase injection | Non-specific IgG (S1) HSTS-26T and U87 | 77     |
| Intravenous collagenase                        | Collagen degradation/decrease in tumor interstitial fluid pressure | 90%–140% increase in uptake at 24 h | TP-3 OHS           | 79     |
| Relaxin infusion                               | Downregulation of tumor fibrosis/ decrease collagen fiber length and signal | 80% increase in diffusion coefficient after a 12-day relaxin infusion | Non-specific IgG HSTS-26T | 78     |
| Intratumoral injection of bovine hyaluronidase | Hyaluronan degradation/decrease in interstitial fluid pressure | 70% increase in uptake 9 days after administration | TP-3 OHS           | 80     |
| Pegylated human hyaluronidase (PEGPH20)        | Tumor hyaluronan degradation           | 100% increase in uptake 2 days after administration | Trastuzumab SKOV3-HAS2 | 82     |
| Pulsed ultrasound                              | Structural modification of extracellular matrix and widening of intercellular gaps | 36% Increase in tumor AUC (0–5 days) | MX-B3 A431         | 130    |
of PEGPH20 to mice bearing SKOV3/HAS2 xenografts increased AlexaFluor488-trastuzumab uptake by 2-fold 48 h after injection. PEGPH20 recently failed to reach the primary endpoint in a phase III clinical trial in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer (NCT02715804). A potential contribution to the failure is dose-limiting toxicities in the phase I trial that limited the PEGPH20 dose to 3 μg/kg, a fraction of the preclinical doses used to improve mAb/chemotherapeutic uptake.

Fibrosis pathway antagonists that can limit matrix deposition in solid tumors have drawn a significant amount of interest. The peptide hormone relaxin-2 decreases transforming growth factor-beta (TGF-β)–mediated fibrosis after binding its cognate receptor relaxin family peptide receptor. Brown et al. used second harmonic generation imaging to evaluate the impact of a 12-day infusion of relaxin on tumor collagen in mice bearing HSTS26T xenografts in dorsal skinfold chambers. Relaxin infusion decreased the length of tumor collagen fibers and decreased the signal of preexisting collagen fibers, resulting in an 80% increase in the diffusion coefficient of a non-specific IgG. Intra-tumoral expression of relaxin using genetically modified hematopoietic stem cells increased trastuzumab efficacy in mice bearing BT474-M1 and HCC1954 xenografts. Currently, there is an interest in using relaxin as a therapy in many fibrotic diseases. However, relaxin recently failed to reach its primary endpoint in a phase III clinical trial for acute heart failure. The clinical success of relaxin may be limited due to its short plasma half-life, and several groups have developed lipid and Fc conjugates with relaxin to extend the persistence of exposure in plasma. An additional concern that may have precluded clinical pursuit of relaxin for anti-cancer treatment is the observation that relaxin signaling is involved in tumor progression and metastasis in several cancers. However, a recent report demonstrated intratumoral relaxin expression decreased metastasis in 4 murine metastatic models, and synergistically increased the efficacy of an anti-PD-L1 fusion protein. There are many other fibrosis pathway antagonists that have been explored both in the clinic and preclinically, including the angiotensin inhibitor losartan, sonic-hedgehog antagonists, and TGF-β inhibitors; however, to our knowledge, the impact of these therapies on co-administered mAb uptake has not been reported. Losartan is currently in a phase II clinical trial in combination with nivolumab and the chemotherapeutic regime FOLFIRINOX for the treatment of localized pancreatic cancer (registration No. NCT03563248).

### Antigen and cellular barriers

Tumor-associated cells can limit mAb tumor uptake and penetration in many ways. The rapid proliferation of cancer cells causes growth-induced solid stress that contributes to the collapse of blood and lymph vessels. Antigen-expressing cells can also act as catabolic sinks, where a small number of tumor cells that surround vasculature can bind to and eliminate a significant portion of extravasated mAbs. Antigen and cellular barriers can act synergistically with tumor vasculature and matrix barriers to decrease mAb tumor uptake and penetration; as a result, approaches to modulate antigen and cellular barriers have been pursued (Table 4).

#### Table 4 Antigen and cellular modulation approaches

| Approach | Impact on mAb tumor PK | mAb/tumor model | Source |
|----------|------------------------|-----------------|--------|
| pH sensitive mAb | 30% increase in tumor AUC (0–14 days) in comparison to non-pH sensitive mAb T84.66 | 10H6/T84.66 | 126 |
| Paclitaxel administered 2 days after mAb administration | 30% increase in cumulated activity 0–6 days | 111In-DOTA-Gly3Phe-m170/breast or prostate cancer | 106 |
| 5-fluorouracil treatment 2 days prior to mAb administration | 148% increase in uptake 5 days after administration | 125I-NHS76 Colon 26 | 107 |
| Paclitaxel treatment 2 days prior to mAb administration | 102% increase in uptake 5 days after administration | 125I-NHS76 Colon 26 | 107 |
| Tofacitinib | 48% increase (LMB) and 133% increase (BV421) in tumor cell uptake/binding 3 h after administration | LMB-100/KLM-1 BV421/MDA-MB-461 | 108 |
| Junction opener 1 | 500% increase in tumor uptake 12 h after administration | Trastuzumab HCC1954 | 109 |
The most clinically relevant approach to overcome cellular barriers to mAb tumor uptake and penetration is the co-administration of traditional chemotherapeutics. In fact, many of the FDA-approved mAb therapies are approved in combination with chemotherapy (Table 1). In a small phase I clinical trial, the mAb $^{111}$In-Gly3Phem170 was administered to patients with breast or prostate cancer on 2 occasions, 1 week apart, and the tumor-accumulated activity was evaluated. One group in the trial received an infusion of paclitaxel 2 days after the second mAb dose. No change in mAb uptake was observed in the control group, whereas a 30% increase in tumor radioactivity was observed between the first and second doses for patients who received paclitaxel. The trough concentrations of trastuzumab in patients who receive paclitaxel were observed to be 1.5-fold higher than those of patients in whom only trastuzumab was administered. The increase in trastuzumab trough concentrations may be the result of paclitaxel killing HER2-expressing tumor cells, decreasing target mediated disposition. In a preclinical study, the co-administration of the chemotherapeutics 5-fluorouracil, etoposide, vinblastine, paclitaxel, or doxorubicin increased the tumor uptake of the radiolabeled tumor necrosis targeting mAbs chTNT-3 and NHS76. Recently, tumor-associated inflammatory cells have been implicated as a non-specific elimination pathway for extravasated mAb. Co-administration of tofacitinib to xenograft bearing mice decreased the number of tumor-associated monocytes, macrophages, and neutrophils. Co-administration of tofacitinib with the immunotoxin LMB-100 or the anti-epidermal growth factor receptor (EGFR) mAb BV421 increased the number of tumor cells with LMB-100 uptake by 48% and the number of tumor cells with BV421 uptake by 133%, 3 h after administration. The same study reported tofacitinib co-administration improved the efficacy of LMB-100 and anetumab ravtansine in xenograft bearing mice. Tumor cells also form tight intercellular junctions that significantly impede antibody penetration. Beyer et al. isolated a small protein named junction opener 1, which decreased the formation of tight junctions between tumor epithelial cells. Administration of 2 mg/kg of junction opener 1 to mice bearing HCC1954 xenografts, 1 h prior to the administration of 10 mg/kg trastuzumab, resulted in a 500% increase in trastuzumab tumor uptake at 12 h. The same study reported junction opener 1 increased the efficacy of trastuzumab against BT474-M1, HCC1954, NCI-N87, and SKOV3 xenografts and increased the efficacy of cetuximab against A549 xenografts.

Cellular antigen kinetics can unfavorably alter mAb disposition and has been implicated as a cellular resistance pathway for mAb therapy. Many tumor-associated antigens, including HER2, CEA, mesothelin, and EGFR, undergo proteolysis that results in the release of soluble antigen (often referred to as shed antigen). Our group observed a 2-fold increase in T84.66 plasma clearance with coadministration of soluble CEA, resulting in a 55% decrease in T84.66 uptake into LS174T xenografts. The tumor uptake of the zirconium-89 ($^{89}$Zr)–labeled anti-EGFR mAb imatuzumab was significantly decreased in mice bearing xenografts of the EGFR shedding cell-line A431 in comparison to the uptake in A549/H441 xenografts with low-EGFR shedding rates. A significant increase in the liver uptake of $^{89}$Zr-imatuzumab was observed in mice bearing A431 xenografts, indicating plasma shed antigen can act as an antibody sink through enhanced non-specific elimination. Iwano et al. developed an anti-CEA mAb, 15-1-32, with preferential binding for membrane CEA. Co-administration of soluble CEA with 15-1-32 decreased the plasma AUC by 22.5%, whereas the plasma AUC of a non-preferential anti-CEA mAb labetuzumab was decreased by 79.9%. Shed mesothelin has also been reported to decrease immunotoxin efficacy. Co-administration of paclitaxel with the immunotoxin SS1P to KB-3-1 xenograft-bearing mice, synergistically increased the anti-tumor effect, which was attributed to a decrease in tumor shed antigen concentrations.

Counterintuitively, high cellular antigen expression has been implicated as a primary barrier to mAb efficacy. High antigen expression and rapid antigen internalization, combined with the slow tumor uptake and the slow interstitial diffusion of therapeutic mAb, result in poor mAb penetration. The limiting effect of antibody binding to tumor antigens on antibody distribution within solid tumors is commonly referred to as the “binding site barrier.” As a result of the binding site barrier, at sub-saturating doses, mAb appears trapped around tumor vasculature. For mAb therapies that can efficiently kill tumor cells with only a fraction of cellular antigen bound, such as antibody–drug conjugates, the binding site barrier results in sub-optimal tumor exposure, decreasing efficacy. Approaches to improve mAb penetration include the use of antibody fragments (Fabs, scFvs, VHVs) or low-affinity mAbs. Antibody fragments can diffuse through the interstitial space more rapidly than intact mAbs, increasing tumor penetration prior to binding. The rapid plasma elimination of antibody fragments requires high fragment doses to
saturate tumor antigen, and high binding affinity is required to retain antigen-binding once plasma concentrations drop below tumor concentrations. However, high-affinity single-chain variable fragments (scFvs) have been shown to have restricted tumor distribution similar to intact mAb, and fragments are unable to recruit immune effector cells. Low-affinity mAbs can diffuse a greater distance from sites of extravasation prior to antigen binding and can undergo multiple dissociation–association steps prior to receptor-mediated internalization and elimination. However, the effective saturation of tumor antigen with a low-affinity mAb requires high mAb doses, decreasing tumor selectivity. Our laboratory developed a pH-sensitive anti-CEA mAb, 10H6, that efficiently detaches from internalized CEA following endosomal acidification. Following antigen dissociation, the pH-sensitive mAb is recycled by neonatal Fc receptor (FcRn) with transport to the interstitial space, allowing 10H6 to undergo multiple CEA binding and internalization events prior to elimination. In comparison to the non-pH sensitive anti-CEA mAb T84.66, 10H6 had a higher tumor and plasma AUC in mice bearing the human CEA expressing mouse cell line MC38. No difference in tumor AUC or plasma AUC was observed for mice bearing the human cell-line LS174T, as 10H6 is a murine mAb and is unable to bind the human FcRn that is expressed in LS174T cells. These results indicate that, following humanization, 10H6, and other pH-sensitive mAbs, can be used, in part, to increase the tumor retention and tumor penetration of mAb. Additionally, it is likely that for solid tumor therapy, mAbs will soon live up to the nickname “magic bullets”.

Conclusions

The dramatic growth of mAb therapies over the past decade has resulted in mAbs becoming one of the most important anti-cancer therapies. Despite the continued growth of mAb therapies, the physiology of solid tumors has significantly limited the efficacy of anti-cancer mAbs. In this review, we have discussed many of the preclinical methods that have been reported to improve mAb tumor uptake and distribution. Many of the early methods relied on co-administered proteins to enhance vasculature permeability or degrade tumor matrix; however, these strategies failed to translate clinically due to poor selectivity. Some of the recent preclinical strategies that are reported to enhance mAb tumor disposition, including tumor-selective vasculature permeability enhancers and pH-sensitive mAbs, may achieve clinical translation in the next several years. Additionally, SMDs that have been shown to impact solid tumor physiology and are approved for other indications, such as losartan or tofacitinib, may be rapidly repurposed to increase mAb efficacy. Also, although not discussed in the present review, simple physical treatments, including hyperthermia or application of ultrasound, have also been demonstrated to improve solid tumor uptake of mAb and may be facilely implemented into clinical protocols. As methods to increase the tumor uptake and distribution of mAb become more selective and more effective, it is likely that for solid tumor therapy, mAbs will soon live up to the nickname “magic bullets”.

Grant support

This work was funded by the National Institutes of Health/National Cancer Institute (Grant Nos. CA204192 and CA246785).

Conflicts of interest statement

Joseph P. Balthasar serves as a consultant for several pharmaceutical companies and as Director of the University at Buffalo Center for Protein Therapeutics, which is supported by an industry consortium.

References

1. Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8: 473-80.
2. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019; 13: 33-51.
3. Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Trans Med. 2018; 7: 11.
4. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012; 26: 447-81, vii.
5. Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016; 27: 2168-72.
6. Hernandez I. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018; 24: 109-12.
7. Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA. How can we improve antibody-based cancer therapy? mAbs. 2009; 1: 67-70.
8. Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016; 107: 107-15.

9. Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS, et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019; 25: 5441-8.

10. Baselga J. Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients? Nat Rev Clin Oncol. 2005; 2: 284-5.

11. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, et al. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in alliance n9831. Breast Cancer Res. 2015; 17: 133.

12. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7: 278.

13. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014; 11: 20-33.

14. Gül N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015; 75: 5008-13.

15. Golay J, Taylor RP. The role of complement in the mechanism of action of therapeutic anti-cancer mAbs. Antibodies. 2020; 9: 58.

16. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018; 48: 434-52.

17. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989; 37: 77-104.

18. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res. 1990; 40: 246-63.

19. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale therapy to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011; 2: 281-98.

20. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990; 9: 253-66.

21. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990; 50: 814s-9s.

22. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987; 47: 3039-51.

23. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48: 7022-32.

24. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987-9.
39. Tewari KS, Sill MW, Long HJ, Pensol RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370: 734-43.

40. Thuerber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PLoS One. 2011; 6 e24696.

41. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A. 1999; 96: 3137-42.

42. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993; 53: 829-36.

43. Li J, Merton DA, Duggaraju R, Thakur ML. Augmenting of tumor uptake of anti-melanoma antibody MEm136: influence of interferon. Nucl Med Biol. 1996; 23: 873-9.

44. LeBerthon B, Khlawi LA, Alaudtin M, Miller GK, Charak BS, Mazumder A, et al. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 1991; 51: 2694-9.

45. Khlawi LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer. 1994; 73: 824-31.

46. Epstein AL, Mizokami MM, Li J, Hu P, Khlawi LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003; 95: 741-9.

47. Roth L, Prahs C, Ruckdeschel T, Savant S, Westrom S, Fantin A, et al. Neurophin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci Signal. 2016; 9: ra42.

48. Sugahara KN, Tellesalu T, Karmali PP, Kotamraju VR, Agemy L, Roth L, Prahst C, Ruckdeschel T, Savant S, Westrom S, Fantin A, et al. Neurophin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci Signal. 2016; 9: ra42.

49. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer. 1994; 73: 824-31.

50. Epstein AL, Mizokami MM, Li J, Hu P, Khlawi LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003; 95: 741-9.

51. Roth L, Prahs C, Ruckdeschel T, Savant S, Westrom S, Fantin A, et al. Neurophin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci Signal. 2016; 9: ra42.

52. Sugahara KN, Tellesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328: 1031-5.

53. Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther. 2014; 13: 651-61.

54. Serlin Y, Shelef I, Knayzer B, Friedman A. Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol. 2015; 38: 2-6.

55. Razpotnik R, Novak N, Curin Serbec V, Rajecvic U. Targeting malignant brain tumors with antibodies. Front Immunol. 2017; 8: 1181.

56. Cavaco M, Gaspar D, Arb Castanho M, Neves V. Antibodies for the treatment of brain metastases, a dream or a reality? Pharmaceutics. 2020; 12: 62.

57. Chang H-Y, Morrow K, Bonacquisti E, Zhang W, Shah DK. Antibody pharmacokinetics in rat brain determined using microdialysis. mAbs. 2018; 10: 843-53.

58. Wang Q, Delva L, Weinreb PH, Pepinsky RB, Graham D, Veizaj E, et al. Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS. 2018; 15: 10.

59. Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020; 20: 26-41.

60. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586-92.

61. Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugs DJ, Hoekstra OS, et al. Molecular drug imaging: 89Zr-bevacizumab pet in children with diffuse intrinsic pontine glioma. J Nucl Med. 2017; 58: 711-6.

62. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med. 1994; 35: 1831-41.

63. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002; 301: 838-51.

64. Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats TS. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Cancer Biol Ther. 2009; 8: 1924-33.

65. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006; 103: 11719-23.

66. Park E-J, Zhang Y-Z, Vykhostseva N, McDannold N. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release. 2012; 163: 277-84.

67. Liu H-L, Hsu P-H, Lin C-Y, Huang C-W, Chai W-Y, Chu P-C, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016; 281: 99-108.

68. Bright C, Reid L, White AL, Genovesi LA, Kokic M, Millar A, et al. MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neuro-Oncol Adv. 2020; 2.

69. Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci. 2019; 12.

70. Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016; 20: 49-52.
70. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis. 1989; 140: 1104-7.

71. Nieskoski MD, Marra K, Gunn JR, Hoopes PJ, Doyley MM, Hasan T, et al. Collagen complexity spatially defines microregions of total tissue pressure in pancreatic cancer. Sci Rep. 2017; 7: 10093.

72. Davies CL, Berk DA, Pluen A, Jain RK. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer. 2002; 86: 1639-44.

73. Dolor A, Szoka Jr FC. Digesting a path forward: the utility of collagenase tumor treatment for improved drug delivery. Mol Pharm. 2018; 15: 2069-83.

74. Eikenes L, Tufto I, Schnell EA, Bjorkoy A, De Lange Davies C. Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res. 2010; 30: 359-68.

75. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008; 22: 276-84.

76. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, et al. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin Cancer Res. 2006; 12: 1906-12.

77. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000; 60: 2497-503.

78. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62: 112-20.

79. Eikenes L, Tufto I, Schnell EA, Bjorkoy A, De Lange Davies C. Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res. 2010; 30: 359-68.

80. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008; 22: 276-84.

81. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, et al. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin Cancer Res. 2006; 12: 1906-12.

82. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000; 60: 2497-503.

83. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008; 22: 276-84.

84. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, et al. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018; 118: 153-61.

85. Mookerjee I, Unemori EN, Du XJ, Tregear GW, Samuel CS. Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann N Y Acad Sci. 2005; 1041: 190-3.

86. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RAD, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009; 23: 1219-29.

87. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, et al. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther. 2011; 19: 479-89.

88. Lee K-C, Hsieh Y-C, Chan C-C, Sun H-J, Huang Y-H, Hou M-C, et al. Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. Lab Invest. 2019; 99: 1203-16.

89. Blessing WA, Okajima SM, Cubria MB, Villa-Camacho JC, Perez-Viloria M, Williamson PM, et al. Intraarterial injection of relaxin-2 alleviates shoulder arthrofibrosis. Proc Natl Acad Sci U S A. 2019; 116: 12183-92.

90. Ikeda Y, Zabbarova IV, Birder LA, Wipf P, Getchell SE, Tyagi P, et al. Relaxin-2 therapy reverses radiation-induced fibrosis and restores bladder function in mice. Neurorul Urodyn. 2018; 37: 2441-51.

91. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al. Effects of serelexin in patients with acute heart failure. N Engl J Med. 2019; 381: 716-26.

92. Chen SA, Perlman AJ, Spanski N, Peterson CM, Sanders SW, Jaffe R, et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res. 1993; 10: 834-4.

93. Muppidi A, Lee SJ, Hsu C-H, Zou H, Lee C, Pfillim E, et al. Design and synthesis of potent, long-acting lipidated relaxin-2 analogs. Bioconjugate Chem. 2019; 30: 83-9.

94. Sun J, Hao W, Fillmore N, Ma H, Springer D, Yu ZX, et al. Human relaxin-2 fusion protein treatment prevents and reverses isoproterenol-induced hypertrophy and fibrosis in mouse heart. J Am Heart Assoc. 2019; 8: e013465.

95. Binder C, Chuang E, Habla C, Bleckmann A, Schulz M, Bathgate R, et al. Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain. Clin Exp Metastasis. 2014; 31: 57-65.

96. Ma J, Niu M, Yang W, Zang L, Xi Y. Role of relaxin-2 in human primary osteosarcoma. Cancer Cell Int. 2013; 13: 59.

97. Hu M, Wang Y, Xu L, An S, Tang Y, Zhou X, et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019; 10: 2993.

98. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4: 2516.

99. Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009; 30: 303-12.
129. Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res. 1997; 3: 63-70.

130. Khaibullina A, Jang BS, Sun H, Le N, Yu S, Frenkel V, et al. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med. 2008; 49: 295-302.

131. Thomas VA, Balthasar JP. Sorafenib decreases tumor exposure to an anti-carcinoembryonic antigen monoclonal antibody in a mouse model of colorectal cancer. AAPS J. 2016; 18: 923-32.

Cite this article as: Bordeau BM, Balthasar JP. Strategies to enhance monoclonal antibody uptake and distribution in solid tumors. Cancer Biol Med. 2021; 18: 649-664. doi: 10.20892/j.issn.2095-3941.2020.0704